World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03528265
Date of registration: 07/05/2018
Prospective Registration: Yes
Primary sponsor: Duke University
Public title: Adapting LFI for Melioidosis
Scientific title: Adapting a Rapid Lateral Flow Burkholderia Pseudomallei Immunoassay in Sarawak, Malaysia
Date of first enrolment: June 21, 2018
Target sample size: 100
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT03528265
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
Malaysia
Contacts
Name:     Gregory C Gray, MD, MPH
Address: 
Telephone:
Email:
Affiliation:  Duke University
Key inclusion & exclusion criteria

Inclusion Criteria:

- Admitted to Kapit Hospital

- Fever more than 3 days and one or more of the following:

- Enlarged cervical, inguinal or axillary lymph nodes (greater than 3 cm in
diameter), painless adenopathy or lymphadenitis or lymph node abscesses

- One or both sides glands involvement such as tender swelling over medial aspect
of the lower eyelid of the lacrimal glands; submandibular glands, parotic glands

- Bedside scan with splenic or liver hypoechoic lesion (less than 2cm in diameter)

- Pneumonia not responding to 48 hours of first line antibiotics

- One or more joint pain with swelling

- Purplish vesicle or bullae mainly over the lower limbs, may resulting in ulcer
after rupture

- Deep seated abscess or brain abscess or genitourinary abscess or osteomyelitis

- Severe sepsis patient with or without shock and/or with multiorgan involvement

Exclusion Criteria:

- Have a clear alternative diagnosis other than melioidosis by a trained health care
professional at the Kapit Hospital

- Have already been treated for melioidosis (e.g. received antibiotics before the start
of the study)

- Are younger than 6 months of age



Age minimum: 6 Months
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Melioidosis
Intervention(s)
Device: Lateral flow immunoassay
Primary Outcome(s)
Proportion of true negative [Time Frame: up to 5 weeks]
Proportion of true positive [Time Frame: up to 5 weeks]
Secondary Outcome(s)
Statistical association between risk factors and test results [Time Frame: up to 3 months]
Secondary ID(s)
Pro00091842
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history